Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K7 | O43318 | 1/20 | 0.46 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.46 |
| ▸ | HSD17B14 | Q9BPX1 | 7/20 | 0.44 |
| ▸ | P4HB | P07237 | 2/20 | 0.43 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.38 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4979980 | 0.87 | MAP3K7 (0.50) | MAP3K7TAB1HSD17B14P4HBHSD17B1 | |
| SCHEMBL4981012 | 0.87 | HSD17B14 (0.49) | MAP3K7TAB1HSD17B14P4HBHSD17B1 | |
| SCHEMBL4726277 | 0.87 | MAP3K7 (0.59) | MAP3K7TAB1 | |
| SCHEMBL4781768 | 0.78 | MAP3K7 (0.59) | MAP3K7TAB1P4HBHSD17B1HSD17B2 | |
| SCHEMBL14273450 | 0.77 | KMT2A (0.50) | P4HB | |
| SCHEMBL4779169 | 0.74 | MAP3K7 (0.60) | MAP3K7TAB1 | |
| SCHEMBL4582870 | 0.74 | MAP3K7 (0.64) | MAP3K7TAB1 | |
| SCHEMBL14273456 | 0.73 | MAP3K7 (0.50) | MAP3K7TAB1HSD17B1HSD17B2 | |
| SCHEMBL4777410 | 0.73 | MAP3K7 (0.50) | MAP3K7TAB1HSD17B1HSD17B2 | |
| SCHEMBL14273453 | 0.71 | TNFRSF1A (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051463-A1 | ANTHRACENE COMPOUNDS AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2008-02-28 | — | — | US | claimed |
| US-20080051463-A1 | ANTHRACENE COMPOUNDS AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2008-02-28 | — | — | US | disclosed |
| US-20080051463-A1 | ANTHRACENE COMPOUNDS AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2008-02-28 | — | — | US | disclosed |
| US-20080051463-A1 | ANTHRACENE COMPOUNDS AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2008-02-28 | — | — | US | disclosed |
| WO-2008015265-A1 | ANTHRACEN DERIVATIVES AND THEIR USE FOR THE TREATMENT OF BENIGN AND MALIGNANT TUMOROUS DISEASES | ÆTERNA ZENTARIS GMBH (DE) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051463-A1 | ANTHRACENE COMPOUNDS AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOR DISORDERS | TUBB1, TUBA1C, TUBB3 | MAP3K7 1090/4885TAB1 981/4885HSD17B14 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.